Clinical Trial Update: The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HAIC + tislelizumab + regorafenib for colorectal liver metastases is underway, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Liver Metastases

Drugs mentioned

• HAIC (hepatic artery infusion chemotherapy)
• Regorafenib (regorafenib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Colorectal Liver Metastases | Phase 2 | Status: UNKNOWN